New hope for low platelets after transplant: baricitinib trial launches
NCT ID NCT07535645
First seen Apr 29, 2026 · Last updated May 14, 2026 · Updated 3 times
Summary
This study tests the drug baricitinib in 28 adults who have dangerously low platelets that did not improve with standard treatments after a stem cell transplant. The goal is to see if baricitinib is safe and can help raise platelet counts without needing transfusions. Participants will receive baricitinib and be closely monitored for side effects and platelet recovery.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Peking University People's Hospital
Beijing, Beijing Municipality, 100044, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.